Navigation Links
Antigen Express to Present at Second Annual "Cancer Immunotherapy: A Long-Awaited Reality" Conference at the New York Academy of Medicine
Date:10/6/2011

tuzumab (Herceptin®).  Only 25% of breast cancer patients have HER-2 levels high enough to be eligible for Herceptin.

A controlled, randomized, and single-blinded Phase II clinical study of AE37 in HER-2 expressing breast cancer patients is currently underway to establish clinical efficacy.  The study endpoint is a reduction in cancer relapse after two years compared to patients not receiving AE37.  There are currently over 200 patients enrolled in the study with either node positive or high-risk node-negative breast cancer.  While positive preliminary results suggested that statistically definitive results could be obtained in 2012, the company opted to enroll an additional 100 patients in early 2011 to ensure sufficient patient numbers.  In particular, these additional patients are required to have low HER-2 expression levels such that they are not eligible for trastuzumab.  It is anticipated that a planned Phase 3 trial will be conducted in this specific patient population.

The many clinical trials conducted in the field of active immunotherapy of cancer over the last decade have provided increasing evidence that it is possible to engage the immune system to focus on and destroy cancer cells. Part of what has been learned over this time is the importance of specific activation of CD4+ T-helper cells in the generation of a robust and effective immune response. Equally clear is the validity of the HER2 protein as a target for cancer therapy. Importantly, HER2 is expressed at low to intermediate levels in a high percentage of breast as well as many other tumor types.  HER2 expression at these levels requires active immunotherapy, such as AE37, rather than passive immunotherapy such as Herceptin. For this reason, the company is continuing with plans for a Phase II prostate cancer study as well as other novel clinical applications of AE37 with interested parties.

"Antigen Express continues to make progress
'/>"/>

SOURCE Generex Biotechnology Corporation
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related biology technology :

1. Antigen Express AE37 Cancer Vaccine Featured in Scientific American
2. Antigen Express Cancer Vaccine Highlighted in Expert Opinion on Biological Therapy
3. Generex Provides Update on Spinout of Antigen Express
4. Generex Announces Publication of Studies with the Mayo Clinic Confirming and Extending the Antigen Express Ii-Key Platform Technology
5. Generex Announces Publication on Application of Antigen Express Technology for Early Detection of Type 1 Diabetes
6. PharmAthene Submits White Paper to BARDA for Advanced Development Funding for SparVax(TM) - Novel Recombinant Protective Antigen Anthrax Vaccine
7. BARDA Announces Modification to Development Approach for Recombinant Protective Antigen Anthrax Vaccines
8. ImaginAb, Inc. and BZL Biologics, LLC Conclude Licensing Agreement for Imaging Rights to huJ591/Prostate-Specific Membrane Antigen (PSMA)
9. Antigen Discovery, Inc. Awarded Grant for Chlamydia Vaccine Development
10. ImmunoVaccine Technologies Licenses Immunotopes Breast, Ovarian and Prostate Cancer Antigens
11. Medicago succesfully expresses VLP antigen for A H1N1 strain
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/27/2014)... 27, 2014 Ryan Carfley , Managing ... to sit down with Bryan Hamilton, the publisher of the ... discuss talent in the Research Triangle region of North Carolina. ... highlighted at the roundtable include the role of social ... of work/life balance and the unique role that Millennials play ...
(Date:10/27/2014)... -- The Italian company Roadrunnerfoot has ... its artificial "lower limb", after the German giant ...      (Photo: http://photos.prnewswire.com/prnh/20141027/713097 ) , ... judgement has arrived: Roadrunnerfoot, the small Italian company ... prostheses with composite materials, has won against global ...
(Date:10/27/2014)... , Oct. 27, 2014 Kalorama Information says ... Ebola concern in the United States ... The healthcare market researcher said the FDA,s Emergency Use Authorization ... diagnostic tests for the detection of the Ebola virus ... useful.  Kalorama routinely assess the IVD industry and its ...
(Date:10/27/2014)... MA (PRWEB) October 27, 2014 ... profit. SoundConnect , an industry leading unified ... its partners and agents to deliver cloud-based audio ... accelerate growth opportunities. , With SoundConnect’s Q4 ... every twenty-five video and/or web conferencing licenses sold, ...
Breaking Biology Technology:Personify's Ryan Carfley Talks Recruiting with Triangle Business Journal, RPG Solutions 2Personify's Ryan Carfley Talks Recruiting with Triangle Business Journal, RPG Solutions 3Italian Lower Limb Prosthesis Company Wins Lawsuit Against German Giant Ottobock 2Kalorama: PCR The Go-to Test in Ebola Fight 2Kalorama: PCR The Go-to Test in Ebola Fight 3SoundConnect Unveils Q4 Partner Incentives 2
... as an acceptable primary endpoint, for ... April 28 /PRNewswire-FirstCall/ - OncoGenex Pharmaceuticals, Inc. (NASDAQ: ... reached an agreement with the U.S. Food and Drug ... 3 registration trial of OGX-011, its lead product candidate ...
... containing microneedles has proven just as effective at ... immunization. A team of researchers at Emory University ... new microneedle skin patch method of delivering flu ... people because of decreased pain, increased convenience, lower ...
... of $264.5 million grows 7.8% year-over-year- Operating margin ... Net quarterly book-to-bill ratio equates to 1.25BOSTON, April ... PRXL ) today announced its financial results for ... three months ended March 31, 2009, PAREXEL,s consolidated ...
Cached Biology Technology:OncoGenex Receives Confirmation from FDA on the Design of a Second Phase 3 Trial Evaluating OGX-011 for the Treatment of Advanced Prostate Cancer 2OncoGenex Receives Confirmation from FDA on the Design of a Second Phase 3 Trial Evaluating OGX-011 for the Treatment of Advanced Prostate Cancer 3OncoGenex Receives Confirmation from FDA on the Design of a Second Phase 3 Trial Evaluating OGX-011 for the Treatment of Advanced Prostate Cancer 4OncoGenex Receives Confirmation from FDA on the Design of a Second Phase 3 Trial Evaluating OGX-011 for the Treatment of Advanced Prostate Cancer 5OncoGenex Receives Confirmation from FDA on the Design of a Second Phase 3 Trial Evaluating OGX-011 for the Treatment of Advanced Prostate Cancer 6Flu vaccine given in microneedle skin patches proves effective in mice 2Flu vaccine given in microneedle skin patches proves effective in mice 3PAREXEL Reports Third Quarter Fiscal Year 2009 Financial Results 2PAREXEL Reports Third Quarter Fiscal Year 2009 Financial Results 3PAREXEL Reports Third Quarter Fiscal Year 2009 Financial Results 4PAREXEL Reports Third Quarter Fiscal Year 2009 Financial Results 5PAREXEL Reports Third Quarter Fiscal Year 2009 Financial Results 6PAREXEL Reports Third Quarter Fiscal Year 2009 Financial Results 7PAREXEL Reports Third Quarter Fiscal Year 2009 Financial Results 8PAREXEL Reports Third Quarter Fiscal Year 2009 Financial Results 9PAREXEL Reports Third Quarter Fiscal Year 2009 Financial Results 10PAREXEL Reports Third Quarter Fiscal Year 2009 Financial Results 11PAREXEL Reports Third Quarter Fiscal Year 2009 Financial Results 12PAREXEL Reports Third Quarter Fiscal Year 2009 Financial Results 13PAREXEL Reports Third Quarter Fiscal Year 2009 Financial Results 14PAREXEL Reports Third Quarter Fiscal Year 2009 Financial Results 15
(Date:10/29/2014)... in New York City on September 19, 2014, leading ... Society Professor of Genome Sciences and Medicine at the ... of Philosophy of Tel Aviv University, was awarded the ... In addition to her honorary degree from TAU, Prof. ... School of Medicine, and for the past 18 years ...
(Date:10/29/2014)... research potential of the Barcode of Life Data ... Biodiversity Data Journal (BDJ) used ... imported these into a human-readable text developed in manuscript ... were used to study the species distributions of ten ... , BOLD is originally designed to support the generation ...
(Date:10/29/2014)... Cancer Genomics of the Kidney consortium ( CAGEKID ... and exposure to aristolochic acid, an ingredient in ... Nature Communications , have important implications for public ... people every year, and in Central Europe incidence ... the International Cancer Genome Consortium (ICGC), has been ...
Breaking Biology News(10 mins):Geneticist and humanitarian: Prof. Mary-Claire King receives Lasker Award 2Go straight and publish: From Barcode of Life Data Systems to scholarly publishing systems 2Kidney cancer in Central Europe 2
... Jewish Medical and Research Center report in the March ... proteins, known as fibulins 3 and 5, slow the ... vessels from sprouting. The proteins are promising candidates for ... fibulin proteins, which regulate cell proliferation, migration and invasion. ...
... A new UCLA imaging study shows that age-related breakdown ... wiring, correlates strongly with the presence of a key ... are detailed in the January edition of the peer-reviewed ... growing body of evidence that myelin breakdown is a ...
... in the home, but the presence of gas stresses out ... from the University of Nottingham have found that changes in ... warning of leaks in natural gas pipelines. "Our study ... monitor gas leaks via the spectrum of reflected light from ...
Cached Biology News:Proteins stop blood-vessel and tumor growth in mice 2Imaging study links key genetic risk for Alzheimer's disease to myelin breakdown 2Plants used to detect gas leaks, from outer space! 2